Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

Slides:

Advertisements

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Advertisements

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Small-Diameter Nerve Fiber Neuropathy in Systemic.

From: Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease Ann Intern Med. 1997;126(11):

Volume 59, Issue 1, Pages (January 2001)

Volume 144, Issue 4, Pages (October 2013)

Copyright © 2014 American Medical Association. All rights reserved.

Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody?

Volume 62, Issue 3, Pages (September 2002)

ILOs of the second lecture

Copyright © 2004 American Medical Association. All rights reserved.

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Nat. Rev. Nephrol. doi: /nrneph

A B Supplementary figure S3 ShCtl ShLCoR LCoR mRNA (%) Optical density

Figure 5 Involvement of B cells in SLE

Applications of the Derivative

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 4 Antinuclear antibodies and disease activity in SLE

Volume 93, Issue 1, Pages (January 2018)

Figure 3 Nucleic acid sensors in SLE

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Volume 94, Issue 4, Pages (October 2018)

Volume 62, Issue 1, Pages (July 2002)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Classical complement pathway activity and disease severity (A) Association between high innate classical pathway (CP) activity and degree of muscle.

A Wolf in Infection's Clothing: The Difficulties of Discerning Systemic Lupus Erythematosus from Its Infectious Sequelae Eric S. Christenson, MD, Colin.

Tom Pettersson, M.D., Matti Klockars, M.D., Teddy Weber, M.D.

Nat. Rev. Rheumatol. doi: /nrrheum

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Systemic Lupus Erythematosus

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Management of Systemic Lupus Erythematosus

Nat. Rev. Rheumatol. doi: /nrrheum

AbH AbF p=0.01 p= p=0.004 p=0.001 Fold increase in 4

Nat. Rev. Rheumatol. doi: /nrrheum

Rickettsia prowazekii infection of endothelial cells increases leukocyte adhesion through αvβ3 integrin engagement Y. Bechah, C. Capo, G. Grau, D. Raoult,

Figure 1 Treat to target, remission and low disease activity in SLE

Jack C. O’Brien, Benjamin F. Chong

Volume 59, Issue 1, Pages (January 2001)

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Outcome study of renal biopsy patients in Okinawa, Japan

Volume 61, Issue 4, Pages (April 2002)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

The Case ∣ Fever, rash, and positive Ehrlichia antibodies

Jack C. O’Brien, Benjamin F. Chong

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Identification of HnRNP-A2/B1 as a Target Antigen of Anti-Endothelial Cell IgA Antibody in Behçet's Disease Sung Bin Cho, Keun Jae Ahn, Do Hee Kim, Zhenlong.

Bilateral Cytomegalovirus Retinitis in a Patient With Systemic Lupus Erythematosus and End-Stage Renal Disease Sabiha Shahnaz, MD, Mamta T. Choksi, MD,

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Representative ultrasound images of patients with SLE

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Volume 68, Issue 5, Pages (November 2005)

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.

Association of MRI findings and serum autoantibodies in diffuse neuropsychiatric systemic lupus erythematosus. Association of MRI findings and serum autoantibodies.

Nat. Rev. Rheumatol. doi: /nrrheum

Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

These data are derived from 21,374 patients with any form of glomerular disease identified in renal biopsy specimens evaluated by the University of North.

Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.

Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Anti-CarALB antibody prevalence and levels in RA and other CTD

Presentation transcript:

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal biopsy of a) anti-PTX3; b) anti-PTX3_2. t1 t2 t3 a b SLE: systemic lupus erythematosus; OD: optical density; t1: time 1, one year before renal biopsy; t2: time 2, at the time of renal biopsy; t3: time 3, one year after renal biopsy; anti-PTX3: antibodies against the long pentraxin 3; anti-PTX3_2: antibodies against the peptide derived from the central part of the long pentraxin 3.